Centessa Pharmaceuticals (CNTA) Research & Development (2020 - 2026)

Centessa Pharmaceuticals (CNTA) has 7 years of Research & Development data on file, last reported at $59.9 million in Q1 2026.

• Research & Development for Q1 2026 came in at $59.9 million, up 79.08% year-over-year; the trailing twelve-month figure through Mar 2026 was $198.7 million (up 23.37% YoY), and the FY2025 annual result was $172.2 million, up 14.63% from the prior year.
• Research & Development climbed to $59.9 million in Q1 2026 per CNTA's latest filing, from $54.5 million in the prior quarter.
• Over five years, Research & Development peaked at $60.9 million in Q4 2024 and troughed at $22.7 million in Q1 2024.
• A 5-year average of $38.9 million and a median of $33.9 million in 2024 frame the typical range for Research & Development.
• The sharpest annual moves came in 2022 and 2023: Research & Development surged 263.37% in 2022, then tumbled 37.24% in 2023.
• A 5-year view of Research & Development shows it stood at $27.8 million in 2022, then advanced by 6.76% to $29.7 million in 2023, then surged by 104.85% to $60.9 million in 2024, then declined by 10.51% to $54.5 million in 2025, then increased by 9.94% to $59.9 million in 2026.
• Business Quant data shows CNTA's Research & Development at $59.9 million in Q1 2026, $54.5 million in Q4 2025, and $41.6 million in Q3 2025.